Methods: We searched Google Scholar, Cochrane Library, ClinicalTrial.Gov, PubMed, and ScienceDirect databases until July 2023. All randomized controlled trials (RCTs) linking intravaginal estrogen supplementation to vaginal atrophy or vaginitis were included. The risk of bias was evaluated with RoB 2, and publication bias was assessed using Egger and Beggs analysis.
Results: All evidence pertains to females. Eighteen studies (n = 4,723) compared estrogen with placebo. Patients using estrogen showed a significant increase in superficial cells (mean differences [MD]: 19.28; 95% confidence intervals [CI]: 13.40 to 25.16; I² = 90%; P < 0.00001) and a decrease in parabasal cells (MD: -24.85; 95% CI: -32.96 to -16.73; I² = 92%; P < 0.00001). Vaginal pH and dyspareunia significantly reduced in estrogen users (MD: -0.94; 95% CI: -1.05 to -0.84; I² = 96%) and (MD: -0.52; 95% CI: -0.63 to -0.41; I² = 99%), respectively. Estrogen did not significantly affect vaginal dryness (MD: -0.04; 95% CI: -0.18 to 0.11; I² = 88%). Adverse events like vulvovaginal pruritis, mycotic infection, and urinary tract infection were reported, but the association was insignificant (risk ratio: 0.95; 95% CI: 0.88 to 1.02; I² = 0%).
Conclusions: Our meta-analysis of 18 RCTs suggests promising potential for intravaginal estrogen therapy in alleviating vaginal atrophy and vaginitis in postmenopausal females.
Abraish Ali,1 Aliha Iftikhar,2 Muzainah Tabassum,2 Rayaan Imran,3 Muhammad Usama Shaid,1 Mahnoor Rehan Hashmi,1 Muhammad Saad,4 Mahnoor Humayun,1 Sidra Imtiaz,5 Eesha Baig1
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Medicine, Ameer-ud-Din Medical College, Lahore, Pakistan.
- Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.